Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
about
Supramaximal dose of candesartan in proteinuric renal diseaseInterplay of vitamin D, erythropoiesis, and the renin-angiotensin systemTaking aim at the extracellular matrix: CCN proteins as emerging therapeutic targetsDetermination of an angiotensin II-regulated proteome in primary human kidney cells by stable isotope labeling of amino acids in cell culture (SILAC)Expression and effect of inhibition of aminopeptidase-A during nephrogenesisCombination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy.Randomized, double-blind, controlled study of losartan in children with proteinuria.Diabetes and drug-associated hyperkalemia: effect of potassium monitoring.Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats.A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patientsAntiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.Genotype-phenotype analysis of angiotensinogen polymorphisms and essential hypertension: the importance of haplotypesImpaired endocytosis in proximal tubule from subchronic exposure to cadmium involves angiotensin II type 1 and cubilin receptors.AT1 receptor antagonism does not influence early radiation-induced changes in microglial activation or neurogenesis in the normal rat brain.Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure.Adverse host factors exacerbate occult HIV-associated nephropathy.Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease?Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db/db mice.Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trialMechanisms of progression of chronic kidney diseaseAngiotensin receptor blockers: therapeutic targets and cardiovascular protection.Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte.Inhibition of renin activity slows down the progression of HIV-associated nephropathyAngiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases.Pharmacological management of renal fibrotic disease.Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.Mechanisms of disease: Fibroblasts--a new look at an old problem.Toward better renoprotection: lessons from angiotensin receptor blockers.Preparing for the worst while hoping for the best: the relevance of hope in the heart failure illness trajectory.New treatment strategies for proliferative lupus nephritis: keep children in mind!Angiotensin receptor blockade has protective effects on the poststenotic porcine kidney.The top 10 things nephrologists wish every primary care physician knewLong-Term and Interactive Effects of Pay-For-Performance Interventions among Diabetic Nephropathy Patients at the Early Chronic Kidney Disease StageRAAS inhibition and mortality in hypertension.Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitorsDirect renin inhibition: extricating facts from façades.
P2860
Q24649685-797B17AE-5ADA-4419-9820-B2ADFF5E02BAQ26822500-226CAE5B-B5EA-474C-99BF-49F3C70D9B2AQ28254386-DF60AD0B-E503-49A3-82AA-A2FB015ABC7FQ28387627-C51C06BA-92AC-48D0-85F1-81F442A0D66CQ28509453-99BDF509-04DB-4C85-B59D-75B5B8A905BFQ33603422-92E15A6A-106D-438B-AA59-6C49A6B39EF4Q33683988-24121E93-D3B2-4841-BC64-45DC8512F004Q33742539-E279BA60-9596-4360-9CF4-8D04589AB96AQ33783689-47BC415A-A400-4381-A436-7B35F61348B0Q33784344-6333942D-7290-4DB8-899C-5DC34F0D7FFAQ34075463-B76E0C1B-9D12-4EFE-AB41-ED8FA854F51EQ34483554-CC96FAB0-23FA-4C5E-BDE2-01671416C084Q34515156-0541856F-6FB8-405C-93DF-5FB3AD937FB0Q35007884-A2C04B08-FFAF-41F0-A3E8-46D12C5DA59DQ35173719-21A70D28-1644-481A-A865-D4AA832FE59DQ35222407-95B87B66-3108-4404-A544-CB1BB0447B5AQ35235846-F36DD19E-96BF-46D2-85E8-98CAB7D3278CQ35640718-0952F8B8-10EF-49C3-87A6-4D9BC08F1A52Q35809946-9F352E06-4DFF-48E3-9270-CA48555337E9Q36036207-915B7DC3-AF21-4A8E-809D-ABCF55C6E9B9Q36079520-F0208A4C-AA50-4D8D-B115-860B2D9229D0Q36120044-B37F9F9F-E84F-42C4-A8DB-CDAA77D7CEE3Q36242608-18104017-2C71-4A32-B6AD-2939A9ED1FF1Q36279580-FCB85D14-3EB0-4285-9C67-D06A4E6D4A0DQ36309378-77BA4F48-0810-4927-85EE-C0B83C009109Q36310340-FA2D4B76-AF6E-407E-9B89-030573AA3C5DQ36407348-7005FDA1-B4B9-46F3-A7BA-6D453B3BE731Q36480076-76C9FDB5-105D-4937-B18A-9CD0926E3A0AQ36577128-CDE14635-0902-4551-8EC1-0AB8ACE3D272Q36777923-DBD7606E-20CA-41B2-94EB-6BF09F74469BQ36839029-74C27AA9-6304-455E-9853-BCE9877A4ED8Q36915693-B260BE81-50F0-4007-9416-4A6610645C82Q37067357-C93E60BB-CA4D-49E0-A41D-F2EC952C60EFQ37148398-585B4230-9BAD-4157-92D6-E86B0ACBB397Q37206790-A1651C5C-5680-4C0C-AEA5-D7F7D737213EQ37659231-90940CFF-64C9-438D-A68A-B9824D9C400DQ37781702-8A4BE566-DB2F-460F-8928-4E940CBB11C2Q37925006-21E9592D-DC24-44D6-ADE9-92D1DEE96DECQ37962590-6B8475A0-BAAB-4A95-904F-479AE1EA40B2Q38088975-74759B0F-DD8F-45FD-BE27-2B88443C4385
P2860
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Combination therapy with ACE i ...... thophysiology and indications.
@ast
Combination therapy with ACE i ...... thophysiology and indications.
@en
type
label
Combination therapy with ACE i ...... thophysiology and indications.
@ast
Combination therapy with ACE i ...... thophysiology and indications.
@en
prefLabel
Combination therapy with ACE i ...... thophysiology and indications.
@ast
Combination therapy with ACE i ...... thophysiology and indications.
@en
P1433
P1476
Combination therapy with ACE i ...... thophysiology and indications.
@en
P2093
Eberhard Ritz
Gunter Wolf
P304
P356
10.1111/J.1523-1755.2005.00145.X
P407
P577
2005-03-01T00:00:00Z
P5875
P6179
1011440471